Towards genomic drug therapy with antisense oligonucleotides.
Antisense oligonucleotides represent a novel class of potential drugs for highly selective blocking of genes. The basic concept of antisense strategy is simple: an antisense molecule recognizes a complementary mRNA (or DNA) by sequence-specific base pairing, and hence prevents translation (or transcription), resulting in a selective inhibition of protein synthesis. Because of these properties, antisense oligonucleotides have great potential as therapeutic agents in several human diseases, such as viral diseases, malignancies and dominant hereditary diseases. However, technical difficulties have slowed down their use as drugs: structural modifications are needed to increase the stability and potency of synthetic oligonucleotides, specific delivery systems are required to facilitate their entry into target cells, and more information is needed to their mechanism of action. Much of the current research on antisense oligonucleotides takes place at the interface of chemistry and biomedical sciences, a multidisciplinary field where finding a common language is sometimes difficult. The aim of this review is to present an overview of the antisense strategy in terms which should be understandable for chemists, biologists and physicians.
Lönnberg
H
H
Department of Chemistry Turku University, Finland.
Vuorio
E
E
D000818:Animals; D004247:DNA / Q000187:drug effects; D004355:Drug Stability; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D012106:Research; D013329:Structure-Activity Relationship; D014777:Virus Diseases / Q000188:drug therapy / Q000235:genetics
D016376:Oligonucleotides, Antisense; D004247:DNA